binimetinib + encorafenib + nivolumab + temozolomide

This is a four-drug combination regimen consisting of binimetinib, encorafenib, nivolumab, and temozolomide. - **Binimetinib** is a MEK inhibitor that targets the MAPK/ERK pathway by inhibiting MEK1 and MEK2 kinases. - **Encorafenib** is a BRAF inhibitor that specifically targets mutant BRAF V600E/K proteins in the same pathway. The combination of these two targeted therapies (BRAF+MEK inhibitors) is used to treat cancers with BRAF V600 mutations, particularly melanoma[1][3][4]. - **Nivolumab** is an immune checkpoint inhibitor targeting PD-1 on T cells, enhancing anti-tumor immune responses[5][6]. - **Temozolomide** is an oral alkylating agent that damages DNA in cancer cells and has been used primarily for brain tumors but also in other malignancies including neuroendocrine neoplasms and melanoma[6][8][10]. The rationale for combining these agents includes targeting tumor cell signaling (binimetinib/encorafenib), modulating the immune response (nivolumab), and inducing direct cytotoxicity (temozolomide). This multi-modal approach aims to overcome resistance mechanisms seen with single or dual-agent regimens.